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Abstract: Intestinal health relies on the association between the mucosal immune system, intesti-
nal barrier and gut microbiota. Bioactive components that affect the gut microbiota composition,
epithelial physical barrier and intestinal morphology were previously studied. The current system-
atic review evaluated evidence of anthocyanin effects and the ability to improve gut microbiota
composition, their metabolites and parameters of the physical barrier; this was conducted in order
to answer the question: “Does food source or extract of anthocyanin promote changes on intesti-
nal parameters?”. The data analysis was conducted following the PRISMA guidelines with the
search performed at PubMed, Cochrane and Scopus databases for experimental studies, and the
risk of bias was assessed by the SYRCLE tool. Twenty-seven studies performed in animal models
were included, and evaluated for limitations in heterogeneity, methodologies, absence of informa-
tion regarding allocation process and investigators’ blinding. The data were analyzed, and the
anthocyanin supplementation demonstrated positive effects on intestinal health. The main results
identified were an increase of Bacteroidetes and a decrease of Firmicutes, an increase of short chain
fatty acids production, a decrease of intestinal pH and intestinal permeability, an increase of the
number of goblet cells and tight junction proteins and villi improvement in length or height. Thus,
the anthocyanin supplementation has a potential effect to improve the intestinal health. PROSPERO
(CRD42020204835).
Keywords: microbiota; polyphenols; short chain fatty acids; intestinal barrier
1. Introduction
A healthy gut includes multiple positive aspects of the gastrointestinal (GI) tract,
specifically, effective digestive and absorptive functions of the intestinal brush border
membrane, and the absence of GI chronic conditions such as enzyme deficiencies, intestinal
bower disease, coeliac disease, colorectal cancer and others. In addition, well-balanced
intestinal microbiota was associated with an effective immune system function that is
required to maintain the host homeostasis [1]. The intestinal microbiota consists of more
than a trillion microorganisms that establish a symbiotic relationship with their host.
These microorganisms prevent the colonization of potentially pathogenic microorganisms
and regulate the mucosal immune system, and thus assist to maintain an intact intestinal
barrier [2]. Thus, the physical barrier of epithelial cells and mucus layer provide the first line
of defense by mechanisms such as microbial recognition, antibodies secretion, antimicrobial
peptides and mucus production [1]. Therefore, impairments of the physical barrier may
enhance the risk of infections, inflammatory intestinal diseases and other diseases occurring
outside the intestine such as immune-related and metabolic disorders [1,3]. In this context,
certain food and plant origin bioactive compounds were investigated to reduce the risk of
the mentioned diseases by acting beneficially on the intestinal health.
Anthocyanins are bioactive water-soluble plant pigments that are responsible for
bright colors, such as purple, red and blue, which are presented mainly as glycosides, with
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the basic structure consisting of an anthocyanidin core attached to sugars and organic
acids [4]. The positive effects of anthocyanins and anthocyanin-rich foods are widely
described in the literature. These effects are mainly associated with reduced risk of diseases
associated with oxidative stress, such as cardiovascular disease [5] and inflammatory
diseases such as diabetes mellitus [6], obesity [7] and insulin resistance [8]. In addition, the
health-promoting effects attributed to anthocyanins were shown to be associated with the
gut microbiota modulation [9].
Dietary anthocyanins undergo a specific metabolism with the absorption rate depend-
ing on their structure. Briefly, anthocyanins cross the gastric mucosa in their intact form.
Thereafter, in the small intestine, mainly in the jejunum, they are absorbed by hydrolytic
enzymes as phenolic aglycone. The unabsorbed anthocyanins reach the colon, and are
metabolized by the colon microbiota, especially by genera and species that are equipped
with enzymes such as β-glucosidase, which are necessary to catalyze the reaction. Intestinal
bacteria such as Bifidobacterium spp. and Lactobacillus spp. possess these enzymes; thus,
the anthocyanin metabolism by microbiota and/or their metabolites can modulate the
growth of these specific bacteria [9–11]. In this sense, the modulation of gut microbiota
by anthocyanin increases the short chain fatty acids (SCFA) producing bacteria, which
acidifies the intestinal pH and inhibits the pathogenic bacteria proliferation, and SCFA as
butyrate act as a fuel to provide energy for epithelial cells, thus improving the intestinal
barrier to avoid the translocation of pathogens and antigens [12]. Thereby, it is suggested
that the potential beneficial functions of anthocyanins could be indirectly attributed to
the gut microbiota modulation and consequent production of metabolites due to bacte-
rial fermentation activities, which improve several parameters related to the intestinal
health [9,13].
Despite the several positive effects of anthocyanins, there is no consensus in the
literature regarding their mechanisms of action on intestinal health in experimental studies.
Recently, a systematic review (n = 6 studies: 3 in vitro, 2 animals and 1 human trial) verified
the effects of anthocyanin supplementation on the gut microbiota composition, showing
the proliferation of healthy anaerobic bacterial population and inhibition of pathogenic
species [14]. However, a healthy gut is maintained by a set of parameters related to the
metabolites of microbial bacteria, intestinal cells’ integrity and the physical barrier [1].
Therefore, the objective of the current systematic review was to investigate the effects of
anthocyanins on several parameters of intestinal health in experimental studies, in order to
understand the mechanism in which these parameters act in association. It is hypothesized
that the supplementation of anthocyanin promotes beneficial changes to the gut microbiota
with increased production of metabolites associated with intestinal barrier improvement,
which contributes to a healthy gut.
2. Materials and Methods
2.1. Eligibility Criteria
The eligibility criteria were based on the PICOS (population, intervention, comparison,
outcomes and study design) model strategy. Duplicate studies were excluded, and the
search and screening for titles and abstracts were carried out independently by the authors
according to the inclusion and exclusion criteria (Table 1).
2.2. Information Source
Two researchers independently searched for original articles. PubMed, Cochrane
and Scopus were used to search studies performed with animal models that evaluated
the effects of anthocyanin on the intestinal health. No time restriction was used. The
descriptors were identified based on Medical Subject Headings (MeSH).
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Table 1. PICOS criteria for inclusion and exclusion of studies.
Parameter Inclusion Criteria Exclusion Criteria
Population In vivo animal studies Clinical studies and in vitrostudies
Intervention





other foods or not measured
Comparator Negative control (without theintervention) No control group
Outcomes
Changes in the gut microbiota
composition, intraluminal pH,
short chain fatty acids,
histological parameters of
small and large intestine, gene
expression of tight junction’s





Study design Experimentalplacebo-controlled studies
Review articles, clinical
studies, theses, dissertations,
book chapters, in vitro
experiments and studies
published in other languages
than English.
2.3. Search Strategy
The following English search terms were used: (Anthocyanin OR Anthocyanidin OR
Anthocyanidins OR Cyanidin OR Delphinidin OR Malvidin OR Peonidin OR Pelargonidin
OR Petunidin) AND (intestinal OR gut). Only articles published in English were considered
in this review. The last search was performed on 2 June 2020. The first selection of the
studies was based on the title and abstract. We excluded review articles, clinical studies,
theses, dissertations, book chapters, in vitro experiments and studies published in other
languages than English. Further, we excluded studies in which the intake of anthocyanin
was associated with other foods, or if the anthocyanin was not measured. Studies were
eligible for inclusion if they fulfilled the following criteria: (a) studies conducted with
animals; (b) the intervention was the intake of foods’ sources of anthocyanin or supple-
mentation with an extract of anthocyanin; (c) the comparator was the negative control
(without the intervention); (d) the outcomes searched were changes related to the intestinal
health, mainly: changes in the gut microbiota composition, intraluminal pH, short chain
fatty acids, histological parameters of small and large intestine, gene expression of tight
junction’s proteins, gene expression of intestinal brush border membrane, integrity of
intestinal barrier and intestinal permeability.
2.4. Selection, Data Collection Process and Data Items
After reading and reviewing the selected research articles in full, the data were com-
pared to ensure integrity and reliability. Divergent decisions were resolved by consensus.
The eligible outcomes evaluated were broadly categorized as follows:
- Gut microbiota: short chain fatty acids (caecal, fecal or in the serum); intraluminal pH
(ileal, caecal or feces); microbial quantification; secretory immunoglobulin A (sIgA);
- Epithelial physical barrier: tight junction proteins; proteins of intestinal brush border
membrane; intestinal permeability; plasm endotoxin;
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- Intestinal morphology: number of goblet cells; length, height and depth of villi and
crypts; mucin secretion; antimicrobial peptides.
Any measure and methodology of these outcomes was eligible for inclusion.
Further, for each experimental study included, we reported relevant information
related to the authors, publication year, country of publication and experimental model
features such as animal model, age, sex, initial weight, number of groups and animal per
group. To access the research methods, we extracted specific information related to the
experimental groups such as type of food intervention, type of diet and control group.
For the control test of food intake, we extracted information related to the method of
administration that was used in the intervention, the duration of the intervention, the
dosage of anthocyanin and main results (control x intervention).
For this review, data from the eligible studies are expressed in tables and figures.
We provided a narrative synthesis of the results according to the main characteristics
and results.
2.5. Study Risk-of-Bias Assessment
The methodological quality of the included studies was assessed, and the risk of bias
was verified using the Systematic Review Centre for Laboratory Animal Experimentation
Risk of Bias (SYRCLE RoB) tool [15], which is responsible for identifying study quality
and measuring the bias in research involving animal studies [16]. The SYRCLE RoB toll
considers ten entries that are related to six types of bias: selection bias, performance bias,
detection bias, attrition bias, reporting bias and other. For each included study, the six bias
types were classified as “high” (+), “low” (−) or “unclear” (?).
3. Results
3.1. Study Selection
The flow diagram of the literature search and selection process was built in accordance
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guideline (Figure 1). After the search in the selected databases, we identified 1155 articles
(x = 495 Pubmed; x = 38 Cochrane and x = 622 Scopus). From these, 1117 were excluded
for the following reasons: duplicate studies (n = 400), title and abstract not suited to the
topic (n = 341), in vitro studies (n = 181), review articles (n = 169), book chapters (n = 11),
supplementation of anthocyanin associated with other foods (n = 9), and other languages
than English used (n = 8). After, 36 articles were read fully. From these, we excluded
nine articles: total of anthocyanin not measured (n = 7); there was no negative control
without intervention (n = 1); and anthocyanins were combined with other compounds
(n = 1). Therefore, 27 studies were included in this systematic review.
3.2. Study Characteristics
The included studies (n = 27) were performed in ten different countries. Most of
them were conducted in China (n = 9) [17–25] or the United States of America (U.S.A.)
(n = 5) [26–30]. Regarding the animal model used in the studies, 15 were performed with
mice [17,20–22,24–34], 11 with rats [18,19,23,35–42] and only 1 with rabbits [43]. Most stud-
ies used male animals (n = 24) [17,18,20–29,31,33–43], but two used female animals [19,30],
and only one study used both male and female animals [32]. Interesting, six studies did
not describe animals’ initial weight [19,21,28,30,32,38]. The age of the animals ranged
from 3 to 72 weeks, although five studies did not mention this information [17,27,35,36,39].
The studies’ main characteristics were chronologically organized by the publication year,
starting with the first published (Table 2).
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Figure 1. Flowchart of the search for articles included in the systematic review, according to PRISMA (2020) recommendation.
The anthocyanin intervention varied by the source that was used. In 20 studies,
diverse fruits were offered in the form of extract (n = 12) [17,19,25,30,32–36,40,41,43], or
as a powder (n = 8) [22,26,28,31,37–39,42]. The fruits used as an anthocyanin source were
chokeberry, Kamchatka berry, apple, blackcurrant, bilberry, blueberry, black raspberry,
red cabbage, grape, berry juçara, jabuticaba, purple carrot, black gojy berry and black
rice. In four studies, the intervention was with purified anthocyanin [20,23,24,27], and in
three studies with monomeric anthocyanidins as cyanidin-3-O-glucoside [18], malvindin-3-
glucoside [29] and pelargonidin-3-O-glucosi e [21].
The form of anthocyanin administration was oral in all included studies, with the form
of administration by addition in the diet (n = 20) [18,22,24–33,35–40,42,43], or via gavage
(n = 5) [17,19,21,23,34] or drinking water (n = 2) [20,41]. The duration of interventions
ranged widely from 1 to 20 weeks. Regarding the anthocyanin dosage, the doses observed
varied from 12.9 mg/ 00 g diet [42] to 1280 mg/100 g diet [40], and 1.68 mg/kg body
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weight (BW) [34] to 200 mg/kg BW [20,24]. In addition, only one study offered a aqueous
extract in the dose of 75 mg/L [41] (Table 3).
Table 2. Characteristics of animal studies on the effects of anthocyanin on intestinal health.




Zdunczyk, 2008 [35] Poland Wistar rats/NS Male 161 ± 8 3 8
Jurgonski, Juskiewicz,
Zdunczyk, 2013 [36] Poland Wistar rats/NS Male 548 ± 36 3 8
Espley, et al., 2014 [31] New Zealand Swiss mice/6–7 wk Male 30 3 10
Jurgonski, et al., 2014 [43] Poland White rabbits/34 days Male 631 ± 26 4 5







Overall, et al., 2017 [26] U.S.A. C57BL/6J mice/6 wk Male 20–30 8 12 or 8
Tong, et al., 2017 [17] China Kunming mice/NS Male 22 ± 5 5 10
Fernández, et al., 2018 [37] Spain Fischer 344 rats/5wk Male 200–270 3 10
Jamar, et al., 2018 [38] Brazil Wistar rats/90 days Male NS 3 7
Lee, et al., 2018 [39] Georgia Wistar rats/NS Male 200–220 3 8
Paturi, et al., 2018 [40] New Zealand Sprague-Dawleyrats/3 wk Male 256–265 8 16
Silva-Maia, et al., 2018 [41] Brazil Wistar rats/3 wks Male 0–100 3 5 or 8
Van Hul, et al., 2018 [33] France C57BL/6J mice/9 wk Male 25–30 4 14
Chen, et al., 2019 [18] China Wistar rats/13 wks Male 403 ± 4 5 8
Cremonini, et al., 2019 [27] U.S.A. C57BL/6J mice/NS Male 20–25 4 10
Gu, et al., 2019 [28] U.S.A. C57BL/6J mice/4 wk Male NS 2 12 or 14
Li, et al., 2019 [19] China SD rats/4 and 12months Female NS 6 10
Liu, et al., 2019 [29] U.S.A. C57BL/6J mice/4–5wk Male 18–21 3 9 or 10
Luo, et al., 2019 [23] China Sprague-Dawleyrats/4 wk Male 100–120 6 8
Peng, et al., 2019 [20] China C57BL/6J mice/5 wk Male 21–24 4 10
Su, et al., 2019 [21] China db/db miceC57BL/6J/6 wk Male NS 2 12
Tian, et al., 2019 [22] China C57BL/6J mice/4 wk Male 15–18 6 11
Zary-Sikorska, et al., 2019 [42] Poland Wistar rats/13 wk Male 146 ± 1.051 5 8
Cao, et al., 2020 [30] U.S.A. C57BL/6J mice/3–18months Female NS 4 3
Peng, et al., 2020 [24] China C57BL/6J mice/5 wk Male 20–24 2 10
Rodríguez-Daza, et al., 2020 [34] Canada C57BL/6J mice/6 wk Male 20–25 6 12
Wang, et al., 2020 [25] China C57BL/6J mice/6 wk Male 19–20 5 12
NS: not specified; wk: weeks; U.S.A.: United States of America; Apc.: adenomatous polyposis coli.
3.3. Main Findings
The reviewed experimental studies demonstrated that the anthocyanin supplemen-
tation provided beneficial effects to intestinal health, and specific improvement in the
intestinal microbiota population, short chain fatty acids production, goblet cell number,
tight junction protein and villi improvement (Table 3).
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Positive findings included the effects on the intestinal microbiome composition and
function. In this context, the majority of the studies observed an increased abundance of
Bacteroidetes [22,23,26,28,30,33]; two studies observed a reduction [18,39]; and one showed
no changes on the abundance of Bacteroidetes [20]. On the other hand, the abundance
of Firmicutes was reduced in five studies [21–23,28,39], and in two studies no changes
were observed [20,30]. Further, a reduction in the Firmicutes/Bacteroidetes ratio (total of
studies that evaluated = 7) was observed in four studies [19,25,27,30];in two other studies,
no changes were observed [20,34], and only one study observed an increased ratio [29].
Further, an increase in Biffidobacterium spp. and Lactobacillus spp. populations were
observed in some of the studies [19,23,25,38,40].
Out of all the studies included, 12 evaluated the production of short chain fatty acids
(SCFA) by bacterial populations. This analysis indicated an increased total SCFA production in
most of the studies (n = 7) [19–22,24,25,42]. Further, four studies reported on a reduction of the
intestinal or cecal pH [22,35,42,43]. Moreover, regarding proteins that are related to intestinal
permeability and function, most of the studies observed an increase in the gene expression
of zonula occludents 1 (ZO-1), occludin, claudin-1 and Mucin (Muc) 2 [20–22,24,25,27,39],
and three studies did not observe these effects [33,34,38]. The intestinal morphology was
evaluated in some of the studies. From seven studies, which evaluated the number of goblet
cells, five studies observed an increased number [17,20,24,25,39], and in the other two studies
no changes were observed [34,40]. In addition, increased villi length or height was reported in
many of the studies [17,18,22,23,25,39]. Four studies [19,21,22,39] observed a reduction in the
serum lipopolysaccharides (LPS), and one study [27] showed a reduction in plasma endotoxin
and intestinal permeability.
3.4. Risk of Bias
From all the studies that were included in the current systematic review (n = 27), the
baseline characteristics, including sex, age and initial weight of animals, were complete
in five studies [18,22,23,31,43]. In most of the studies, the allocation of animals was not
described in detail, since there was no information about the randomization process.
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Six studies did not mention if the animal allocation to treatment groups was performed
randomly [20,21,25,27,37,39]. Furthermore, none of the studies reported about blinding
the investigators involved in the research. Four studies did not include all animals in the
analysis, and the exclusion criteria were not reported [21,27,32,41] (Figure 2).
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4. Discussion
In this systematic review, we evaluated the effects of anthocyanins or their extract on
intestinal health parameters, in vivo. Therefore, this systematic review verified that food
sources of anthocyanin or its extract are able to improve intestinal parameters changed by
pathologic conditions or dietary patterns.
The animal models of the studies included were high fructose diet, high fat diet,
intestinal mucositis, colorectal cancer, damage to the intestinal mucosa, diabetes and old
animals. It is highlighted that all of these models promote intestinal changes, such as
increased intestinal permeability, inflammation, altered morphology and changes in the
intestinal microbiota composition such as dysbiosis. Despite different animal models being
used in the studies, all of them except one [43] used rodents as the animal. Similarly as in
humans, Bacteroidetes and Firmicutes are the two main phyla in rodents’ gastrointestinal
tract. In this sense, microbiota composition in rodents is usually analyzed in interventions
that study the casual role of gut microbiota in diet, health and disease interaction [44].
Since all animal models used in the studies of this review promote modification of the gut
microbiota at some level, the choice of the best model depends on the main goal of the
study [44]. Therefore, bioactive components with functional properties were investigated
to verify their potential beneficial effects on intestinal health [7]. Anthocyanins are soluble
components, from the class of flavonoids, with functional dietary properties that were
previously associated with oxidative stress inhibition, antioxidant activity and intestinal
microbiota modulation [45]. Further, the supplementation of anthocyanin cyanindin-3-O-
glucoside for eight weeks in Wistar rats was able to restrain the gut microbial dysbiosis
that was induced chemically, by suppressing the decrease of Rothia and Romboutsia and the
increase of Clostridium verified in the disrupted gut microbiota [18].
In this review, the anthocyanin dietary intake induced increased abundance of Bac-
teroidetes and a reduction of Firmicutes. A reduction of the Firmicutes/Bacteroidetes ratio in
the caecal content was observed in experimental in vivo models of high fat diet [25,27]. In
recent years, research with animal models in samples of caecal content [23] and humans in
fecal samples [46] demonstrated that obese organisms have a high abundance of Firmicutes
and a low abundance of Bacteroidetes. These changes in the microbial composition result
in an increased absorption of calories, reduced secretion of anorexigenic hormones and
intestinal barrier damage [46]. Bacteroidetes and Firmicutes are the two main phylum that
inhabit the large intestine, corresponding to 90% of total bacteria [47]. The Firmicutes phy-
lum and gram-positive bacteria carry more enzymes that are required for carbohydrates
metabolism, which contribute to their transport and energy absorption [48], besides higher
fat deposition in adipocytes [49].
Following anthocyanin consumption, most are not absorbed in the upper gastroin-
testinal tract, and therefore reach the colon intact [11]. At the colonic level, anthocyanins
are metabolized by the local microbiota, initially via deglycosylation, and is followed by
a secondary degradation into phenolic acids, mainly protocatechuic, vanillic, syringic,
gallic and p-coumaric [45]. The main bacterial populations that are able to metabolize
anthocyanin are the Bifidobacterium spp. and Lactobacillus spp., which have probiotic effects,
including the production of antimicrobial substances, competition with pathogens for
adhesion to the epithelium and nutrients, immunomodulation and inhibition of bacterial
toxin production [50]. In addition, these bacteria have enzymes such as β-glycosidase that
are needed to catalyze reactions that release the glycose from the aglycon and provide the
energy needed for bacterial populations to prosper [12]. In several studies included in this
review, an increase of Bifidobacterium and Lactobacillus was documented [19,23,25,38,40]. In
this context, 20 day intake of dealcoholized red wine in healthy adults increased the fecal
concentration of Bifidobacterium, Enterococus and Eggerthella lenta. In addition, in this study,
the produced metabolites associated with the increase of Bifidobacterium were those derived
from anthocyanin degradation (4-hydroxybenzoic, syringic, p-coumaric, homovanillic
ácidos) [51]. Bifidobacterium is related to pathogen inhibition by organic acids production,
antimicrobial peptides and immune stimulation [52]. Besides this, among the acids pro-
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duced by the microbial metabolism of anthocyanin, protocatechuic acid presents inhibitory
effect on pathogenic bacteria growth [53], and gallic acid is effective in reversing changes in
the microbiota caused by induced colitis in animals, by reducing Firmicutes and Proteobacte-
ria and increasing Bacteroidetes [54]. Therefore, the beneficial effects that are associated with
anthocyanin consumption may be achieved by its metabolites post-degradation.
Some of the physiological properties of the gut microbiota are attributed to fermen-
tation of non-digestible carbohydrates by anaerobic bacteria, producing short chain fatty
acids (SCFA) [47]. In this review, the dietary supplementation of anthocyanin was able to
increase the production of total SCFA (acetate, propionate and butyrate) in the majority of
the studies. SCFA act as a fuel to intestinal cells by stimulating the cellular proliferation.
The production of SCFA also reduces the intraluminal pH, which limits the growth of
pathogenic bacteria due to the acidification [55,56]. Therefore, SCFA assist to maintain
the intestinal epithelium integrity, and protect the host from potential immune and in-
flammatory diseases [56]. In a mice study, where diet included anthocyanin extract, SCFA
production increased due to elevated microbial activity, specifically of Bifidobacterium and
Lactobacillus [25]. Further, the increased abundance of Roseburia is associated with a higher
production of SCFA in the intestine, and the abundance of Akkermansia was associated
with propionic production [23]. SCFA also have an immunomodulatory effect by pro-
moting the development of mucosal regulatory T cells (Tregs) through the interaction
with the G protein-coupled receptor (GRP43) and the inhibition of histone deacetylases
(HDACs) [57,58]. Furthermore, SCFA exert positive effects to the turnover and differenti-
ation of colonic epithelial cells, and to stimulate the mucus production that prevents the
pathogenic bacteria adherence [56]. It is suggested that these acids activate the mammalian
target of rapamycin (mTOR) complex and the STAT3 (signal transducers and activator of
transcription 3) in the intestinal epithelial cells, which promote the expression of antimicro-
bial peptides as β-defensin and RegIIIγ [59]. From the included studies in this systematic
review, two observed an increase of Lysosome-1 (Lyz1) peptide, which acts to maintain the
microbiota homeostasis and to eliminate commensal microorganisms [21,33]. Therefore, by
these mechanisms, SCFA act to maintain the epithelial barrier integrity [60,61].
The intestinal epithelial barrier consists of a mucus layer and cells attached by a
protein complex, including tight junctions, adherents junctions and desmosome [62]. The
tight junctions complex is composed by proteins as claudins, occludin, junctional adhesion
molecule (JAM-1) and zonula occludents (ZO-1), and the rupture in some of these proteins
increases the paracellular permeability with permeation of pro-inflammatory molecules,
immune activation and inflammation [63]. In this review, the majority of the included
studies verified an increase in the gene expression of ZO-1, occludin and claudin 1. The
anthocyanin has an anti-inflammatory effect through inhibition of the factor nuclear kappa
B (NF-kB), and via regulation of I-Kappa-B-alpha (IkBα) phosphorylation that decreases
the gene expression of pro-inflammatory cytokines, such as tumor necrosis factor alpha
(TNF-α), interferon gamma (IFNγ) and interleukins [64,65]. These cytokines are related to
intestinal barrier damage by harming the tight junction protein expression [66]. The TNF-α
promotes changes in the tight junctions via its receptor tumor necrosis factor receptor
1 (TNFR-1), so that anti-TNF strategies promoted tight junctions’ rearrangement with
an improvement of occludin and ZO-1 [67]. Therefore, the anthocyanidin cyaniding-3-
glucoside (C3G) was able to inhibit the IkBα phosphorylation and the nuclear translocation
of NF-kB (p65), and these effects were associated with the nuclear transcription factor
Nrf2 (erythroid-2-related factor 2) that induces the expression of antioxidant enzymes [68].
Therefore, the anthocyanin can act directly or indirectly to improve tight junction’s integrity.
Moreover, the intestinal epithelial cells are covered by a mucus layer produced and
secreted by the goblet cells. The mucus is composed of glycoproteins of mucins, mainly
Muc2, forming a viscous layer that protects against pathogen invasion by preventing
the sites of binding for bacteria [69,70]. The discontinuous mucus layer in the cecum
of rats are considered hotspots for Salmonella; thus, the absence of the mucus layer can
lead to infections’ development [71]. In addition, the increase in goblet cell number,
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mainly those classified as acids, promotes barrier function improvement by increasing
the mucin secretion that prevents pathogen invasion and possible intestinal inflammation
due to acidic mucin resistance to degradation by bacterial glycosidase and has higher
viscosity [72]. SCFA also contribute to the intestinal cell proliferation since they stimulate
the proliferation and differentiation of enterocytes [73]. Thus, there is evidence that the
inflammasome nucleotide-oligomerization domain-like receptor 6 (NLRP6), expressed
mainly on enterocytes, controls the mucin secretion and the mucosa renewal by the goblet
cells [74]. A previous study with rats suggested that SCFA can activate the colonic NLRP6,
thus protecting the intestinal barrier [75]. Considering this evidence, it is verified that the
mulberry (50 mg anthocyanin/kg diet) supplementation in animals with induced colitis
resulted in an increase in goblet cells and NLRP6 expression, therefore suggesting a link
between mucin secretion and antimicrobial peptide production [76].
In order to optimize the digestion and absorption of nutrients, the gut (duodenum)
morphology is unique and organized in villi [77]. It is observed that anthocyanins are
related to an improvement of the absorptive function by increasing the villus length, villus
length/crypt depth ratio and the total mucosa thickness [78]. These intestinal morphology
changes result in a better intestinal digestion and absorption, since they assure a higher
absorption surface, brush border enzyme expression and nutrient transport system [79].
Disruption of the intestinal barrier integrity can be occasioned by tight junction disrup-
tion and mucus layer depletion, thus allowing the paracellular translocation of bacteria and
their components, such as lipopolysaccharides (LPS) [63]. Of the included studies in this
systematic review, a few evaluated the endotoxemia; however, of these, the anthocyanin
supplementation was able to reduce the intestinal permeability, endotoxemia and the
levels of serum LPS [19,21,22,27,39]. LPS are cellular wall components of gram-negative
bacteria that contain a pathogen-associated molecular pattern, Lipid A, able to interact with
Toll-like Receptor 4 (TLR-4) via the Myeloid differentiation primary response 88 (MyD88)
protein [80]. This interaction results in the activation of the pathway downstream and Nf-
kB translocation, thus increasing the gene transcription of cytokines such as TNF-α, IL-1β
e and IL-6 [80,81]. The analysis of monocyte from obese individuals supplemented with
berry juçara (5 g/day; 131.2 mg total anthocyanins) for six weeks observed the reduction
of mRNA (messenger ribonucleic acid), TLR4 and the protein expression of MyD88 [82].
Therefore, it is known that the inflammation mediated by LPS can exert local and systemic
effects and be related to gastrointestinal diseases, such as Crohn disease [83], inflammatory
bower disease [84] and metabolic disorders as diabetes mellitus type 2 [85] and obesity [86].
Animal experiments assist to design clinical studies in terms of doses, duration, type
of intervention and other topics [15]. In this context, the positive changes observed at the
gut microbiota following anthocyanin supplementation and consumption in the animal
studies included in this review corroborate with results verified in several clinical studies.
Cranberry consumption (30 g, with 83.7 mg anthocyanin) for five days by healthy adults
resulted in increased abundance of Bacteroidetes and decreased abundance of Firmicutes [87].
Further, the intake of dealcoholized red wine for 20 d (9.72 mg anthocyanin) increased
the fecal concentration of Bifidobacterium and Enterococus [51]. Thus, we highlighted the
complexity of animal models of gut microbiota, which are able to tolerate the presence and
effects of dietary components such as anthocyanins in a similar manner as described in
human studies. Further, animal model studies related to anthocyanin supplementation
are effective in demonstrating the safety and efficacy of their consumption. Hence, these
aspects are relevant and important for the translation of results and adaptation to clinical
studies, and in order to establish dietary guidelines for humans.
Finally, systematic reviews guarantee the gathering of evidence related to a specific
topic; therefore, they obtain conclusions with greater scientific rigor. The evidence verified
in this review, performed with 27 studies, demonstrates that the anthocyanin dietary intake
is beneficial and improves specific parameters such as the gut microbiota composition,
short chain fatty acids production and the intestinal physical barrier, such as the increase of
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tight junction protein and goblet cell number, and the reduction of intestinal permeability,
that together promote intestinal health.
Dosage and Reporting Quality
This systematic review showed high heterogeneity among the studies, with several
experimental models used, distinct methodologies in the intestinal parameters analyzed
and high variation related to dose and time of anthocyanin supplementation. Probably,
these variations were observed because of the large number of studies included. The antho-
cyanin supplementation dose ranged from 12.9 mg/100 g diet as dried purple carrot [42]
to 1280 mg/100 g diet as extract [40]. The supplementation as an extract allows for the
delivery of a higher dose of anthocyanins, since it concentrates the components, while the
anthocyanin intake in its food source provides a lower dose, based on average daily intake
of the animal. Hence, the safety of anthocyanin intake were tested and approved in animals,
indicating no toxicity or any adverse effects to animal health, even at a high dosage [88]. In
addition, studies showed that the anthocyanin supplementation exposure period varied
from 1 week [17,38] to 20 weeks [37]. Analyzing the outcomes individually, the time of
supplementation from 1 to 12 weeks promoted the increase of Bifidobacterium and Lacto-
bacillus, the production of SCFA and an improvement of goblet cells and villi length or
height; further, the increase of proteins related to intestinal permeability was verified from
the time of 1 to 14 weeks of intervention. Thus, for the design of studies for new researches
evaluating the effects of anthocyanin on intestinal health, this range of time should be
considered in accordance with the goal of the research. Beneficial effects of anthocyanin
supplementation were observed even in the lowest dosage [42] and the shortest exposure
period [17,38]. Furthermore, most of the reviewed studies observed that anthocyanin
was quantified as total anthocyanin; however, few studies showed its profile, as specific
monomers of anthocyanidin such as cyanidin galactoside [31], cyanidin-3-O-glucoside [18],
malvindin 3-glucoside [29] and pelargonidin-3-O-glucoside [21].
This systematic review evaluated the effects of dietary anthocyanin in the context of
its potential intestinal health-promoting effects, such as beneficially changing the intesti-
nal microbiota, increasing the short chain fatty acid production, reducing the intestinal
permeability and improving parameters related to the intestinal physical barrier such as
tight junctions protein and goblet cell number. The studies’ selection was based on method-
ologies that are recommended and approved for systematic review, thus allowing reliable
conclusions. The risk of bias was evaluated according to the SYRCLE RoB tool [15], which
establishes consistency and avoids discrepancies to evaluate the risk of bias from animal
studies. Twenty-one (n = 21) studies did not show the animals’ completed baseline char-
acteristics, and none of the studies showed information about whether researchers were
blinded from knowledge of the intervention groups and/or the outcome assessor. In this
sense, the absence of some baseline characteristics probably had no influence on the main
conclusion of this review, since those characteristics were not comparable among studies.
On the other hand, the risk of bias related to blind researchers and outcome assessors could
have influenced the results of outcomes in each study. However, the conclusion of this
review was performed with a large number of studies in association; thus, these biases
may not represent a major impact on the main conclusions, considering the methodologic
rigor that this review followed. Further, the risk of bias in analysis may represent a lack of
information regarding the experimental design of animal studies, showing that progress is
needed in this field. Therefore, we suggest that research performed with animals follows
the SYRCLE protocol to avoid a lack of information in the studies.
5. Conclusions
The scientific evidence from the reviewed in vivo studies demonstrates that the sup-
plementation of anthocyanin is effective to modulate the intestinal microbiota through
the increase of Lactobacillus spp. and Bifidobacterium spp., and to increase the production
of short chain fatty acids. In addition, the reviewed studies observed an improvement
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in the intestinal barrier by the increased expression of tight junction protein associated
with an improvement of cells’ morphology and mucus production, which reduces the
potential risk of inflammation (Figure 3). We highlighted that these intestinal changes in
association may be the mechanisms by which upon anthocyanin supplementation that
ranged from 1 to 14 weeks with the dosage that ranged from a 12.9 to 1280 mg/100 g diet
exert beneficial effects on intestinal health. We consider that it is not adequate to establish a
specific dose and a specific time to achieve all of these effects in association, since different
animal models, methodologies and large ranges of time and dose of anthocyanin supple-
mentation were observed. However, considering the methodological rigor that this review
followed, the dose and time intervention ranges observed could be used as guidelines for
future researchers. Despite the limitation of extrapolating animal results to human, with
knowledge of all of the benefits observed, we consider that the daily intake of foods’ source
of anthocyanin should be stimulated, with the population acting as a strategy to prevent
health problems.
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